Abstract 1025: Clinical outcomes and differential tumor immune microenvironment in patients with small cell lung cancer and paraneoplastic syndromes
Wade T. Iams(Vanderbilt University Medical Center), Christine M. Lovly(Dana-Farber Cancer Institute), Catherine B. Meador(Vanderbilt University Medical Center), Joseph T. Schneider(Vanderbilt University Medical Center), Eileen Shiuan(Vanderbilt University), Marc Roth(Vanderbilt University), Jeremy L. Warner(Brown University), Christine Vaupel(Navidea Biopharmaceuticals (United States)), Lucy Lu Wang(Vanderbilt University Medical Center), Zhiguo Zhao(Vanderbilt University), Jennifer Bordeaux(Lineage Cell Therapeutics (United States))
Cited by 0
Related Papers
<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers
|Journal of Clinical Oncology|2012|1.6k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Mechanisms of receptor tyrosine kinase activation in cancer
|Molecular Cancer|2018|1.1k
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
|Journal of the National Comprehensive Cancer Network|2021|1k
Non–Small Cell Lung Cancer, Version 4.2024
|Journal of the National Comprehensive Cancer Network|2024|805